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I. INTRODUCTION 
 
Solid oral drug delivery is the simplest and easiest way of administering drugs. 
Thesedosage forms have many advantages over other types of oral dosage forms. Therefore, 
most of the New Chemical Entities (NCE) under development are intended to be used as a 
solid dosage forms that originate an effective and reproducible in vivo plasma concentration 
after oral administration.  
 
The aqueous solubility of a drug is one of the key physical properties that affect both 
its ADME profile and ‘screenability’ in High Throughput Screening (HTS).Solubility is the 
characteristic physicalproperty referring to ‘the ability of a given substance, the solute, to 
dissolve in asolvent’. Enhancement of oral bioavailability of poorly water soluble drugs 
remains one of the most challenging aspects of drug development. Solubility and dissolution 
are the rate determining steps in drug absorption.  
 
Table 1: Solubility Terms (According to USP) 
 
 
 
 
 
 
 
 
 
 
 
      Nearly 40 % of the drug molecules that have been discovered are lipophilic in nature. 
 
 
 
Definition 
Parts of solvent required for 
one part of solute 
Very Soluble <1 
Freely Soluble 1-10 
Soluble 10-30 
Sparingly Soluble 30-100 
Slightly Soluble 100-1000 
Very Slightly Soluble 1000-10,000 
Insoluble > 10,000 
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Table 2:  Biopharmaceutical Classification System (According to BCS 
classification by FDA) 
Class Description 
Class I Highly soluble, highly permeable 
Class II Poorly soluble, highly permeable 
Class III Highly soluble, Poorly permeable 
Class IV Poorly soluble, Poorly permeable 
 
 
Figure 1: Graphical representation of Biopharmaceutical Classification System (Gaurav 
Tiwari et al., 2009) 
 
1.1Dysphagia Fast Disintegrating Tablets (FDTs) 
Dysphagia,1-8 or difficulty in swallowing, is common among all age groups. Accordingto a 
study by Sastry et al., dysphagia is common in about 35% of the generalpopulation, as well as 
an additional 30–40% of elderly institutionalized patients and18–22% of all persons in long-
term care facilities. Common complaints about the difficulty in swallowing tablets in the 
order of frequency of complaints are size, surface,form, and taste of tablets. Geriatric and 
pediatric patients and traveling patientswho may not have ready access to water are most in 
need of easy swallowing dosageforms. Another study shows that an estimated 50% of the 
population suffers from this problem. These studies show an urgent need for a new dosage 
form that canimprove patient compliance.Solid dosage forms that can be dissolved or 
suspendedwith water in the mouth for easy swallowing are highly desirable for the 
pediatricand geriatric population, as well as other patients who prefer the convenience 
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ofreadily administered dosage forms.Although chewable tablets have been on themarket for 
some time, they are not the sameas the new ODTs.  
Patients for whom chewingis difficult or painful can use these new tabletseasily. ODTs can 
be used easily in childrenwho have lost their primary teeth but do nothave full use of their 
permanent teeth. Recent market studies indicate that more thanhalf of the patient population 
prefers ODTs toother dosage formsand most consumerswould ask their doctors for ODTs 
(70%),purchase ODTs (70%), or prefer ODTs toregular tablets or liquids (>80%).During the 
last decade, fast disintegrating tablet (FDT) technologies thatmake tablets disintegrate in the 
mouth without chewing and additional waterintake have drawn a great deal of attention.  
  The FDT is also known as fast melting,fast dispersing, rapid dissolve, rapid melt, and/or 
quick disintegrating tablet. AllFDTs approved by the Food and Drug Administration (FDA) 
are classified asorally disintegrating tablets. Recently, the European Pharmacopeia adopted 
theterm orodispersible tablet for a tablet that disperses or disintegrates in less than 3minutes 
in the mouth before swallowing. Such a tablet disintegrates into smallergranules or melts in 
the mouth from a hard solid to a gel-like structure, allowing easy swallowing by patients. The 
disintegration time for good FDTs varies fromseveral seconds to about a minute. 
 
1.2Advantages of FDTs 
 FDTs have all the advantages of solid dosage forms, such as good stability, 
accuratedosing, easy manufacturing, small packaging size, and easy handling by 
patients. 
 FDTs also have the advantages of liquid formulations, such as easy administration and 
no risk of suffocation resulting from physical obstruction by a dosage form. 
 Theprimary patients for FDTs are pediatric, geriatric, and bedridden or 
developmentallydisabled patients; patients with persistent nausea; and patients who 
have little orno access to water.  
 Application of FDTs can of course be extended to more generalpatients of daily 
medication regimens. From the pharmaceutical industry’s point of view, FDTs can 
provide new dosage forms as a life cycle management tool for drugsnear the end of 
their patent life. 
 Because the tablets disintegrate inside the mouth, drugs may be absorbed in thebuccal, 
pharyngeal, and gastric regions. Thus, rapid drug therapy intervention andincreased 
bioavailability of drugs are possible.  
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 Because the pre-gastric drug absorption avoids the first-pass metabolism, the drug dose 
can be reduced if a significantamount of the drug is lost through the hepatic 
metabolism. 
 
Disadvantages: 
 Drugs that are absorbed at a specific site cannot be given in these dosage forms 
 Requires special packaging as the tablets show high Friability which is expensive 
 Suitable for low dose drugs 
 
1.3. DESIRED CHARACTERISTICS AND DEVELOPMENT CHALLENGES OF 
FDTs: 1-3 
Because of administration of FDTs is different from administration of conventional tablets, 
the FDTs should maintain several unique properties, as listed below. 
A. Fast Disintegration 
FDTs should disintegrate in the mouth without additional water or with a verysmall amount 
(e.g., 1–2 mL) of water. The disintegration fluid is provided by the saliva of the patient. The 
disintegrated tablet should become a soft paste or liquidsuspension, which can provide good 
mouth feel and smooth swallowing. The “fastdisintegration” usually means disintegration of 
tablets in less than 1 minute, but itis preferred to have disintegration as soon as possible. 
B. Taste of Active Ingredients 
Because of FDTs dissolve or disintegrate in the patient’s mouth, the drug will be partially 
dissolved in close proximity to the taste buds. After swallowing, there shouldbe minimal or 
no residue in the mouth. A pleasant taste inside the mouth becomescritical for patient 
acceptance. Unless the drug is tasteless or does not have an undesirabletaste, taste-masking 
techniques should be used.  
An ideal taste-masking technology should provide drugs without grittiness and with good 
mouth feel. The amount of taste-masking materials used in the dosage forms should be kept 
low “AS LOW AS POSSIBLE” to avoid excessive increase in tablet size. The taste-
masking technology should also be compatible with FDT formulations. For example, if drug 
particles are coated to minimize unpleasant taste, the coating should notbe broken during 
compression or dissolved during wet granulation. Taste masking of bitter tasting drugs is 
critical to the success of the FDT formulations. 
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Physiology of Taste: 20, 29 
Physiologically, taste is a sensory response resulting from a chemical stimulation of taste 
buds on the tongue (Fig. 2). Bitter molecules bind to a G protein-coupled receptor type T2R 
on the apical membrane of the taste receptor cells (TRC) located in the taste buds. In humans, 
roughly 25 different T2R are described. Additionally, several alleles are known and about 
100 different bitter phenotypes exist in man. TRC are specialized to a certain taste quality.  
For the bitter modality, one TRC expresses more than one T2R type but not in all variants. 
On the other hand, it is now known that one particular bitter compound can bind to several 
T2R subtypes with distinct affinity and that at least some of the bitter receptor proteins, e.g., 
the hT2R47, are broadly tuned for several structural classes of bitter molecules. As a result, a 
bitter taste pattern for the cells occurs in a similar way to the olfaction process; however, the 
final signal to the brain is mainly “negative” or “bitter”.  
Following the binding of agonists to the T2R, phospholipase C is activated via a β-subunit of 
a G protein of the TRC which activates the IP3 (inositoltriphosphate) pathway in the cell. 
Calcium will be released from internal stores and at least the co-expressed ion channel 
TRPM5 will be activated and the cell depolarizes. In addition, the α-unit of the TRC-specific 
G protein gustducin may activate the PDE pathway of transduction. 
 
                                          Fig. 2Structure of taste bud 
 
C. Taste-masking techniques:3-6 
The methods most commonly involved for achieving taste masking include various chemical 
and physical methods, which prevent the drug substance from interacting with taste buds. 
Various methods used for taste masking are: 
-Addition of Flavouring and Sweetening agents 
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- Inclusion complexation 
-microencapsulation 
-Complexation with ion exchange resin 
-Granulation 
-Gel Formation 
-multiple emulsion 
-Bitterness Inhibitor 
-prodrug approach 
 
Taste masking with flavours, sweeteners, and amino acids:  
It is known to most food technologists that bitter taste can be masked by strong flavours, 
especially by using so-called congruent flavours. These flavours cause a certain acceptance of 
bitterness due to their inherent occurrence. 
Artificial sweeteners and flavours are generally being used along with other taste-masking 
techniques to improve the efficiency of these techniques. The unpleasant taste of certain 
formulations like mouthwashes and cough drops containing medicinal and bitter tasting 
substances such as eucalyptus oil can be masked by adding fenchone, borneol, or isoborneol. 
Cocoa or chocolate flavours preparations mask the bitterness of quinine (Becker et al. 1951), 
grapefruit flavours are widely used to mask pharmaceutical actives. In cola-type beverages, 
most consumers cannot detect the bitterness of caffeine due to the high dosage of sucrose, 
sweetener and acid. Another classical system is the suppression of bitterness by sodium salts. 
Sodium saltswhich are low in saltiness such as gluconate or acetate are the most successful 
maskers (Keast et al. 2005). A combination of sodium salts and L-arginine was used for the 
reduction of bitterness of certain peptides (Uchida et al. 2004). 
Aspartame is used as a prominent sweetener in providing bitterness reduction. A very small 
concentration (0.8%) is effective in reducing the bitterness of 25% acetaminophen. Starch, 
lactose, and mannitol have also exhibited taste-masking properties of caffeine. 
The mechanisms of the aforementioned bitter-masking technologies are not known. Probably, 
the masking activities are mostly caused by psychophysical effects due to the suppression of 
the off-taste by camouflage. Unfortunately, the use of strong flavours or tastants is not 
acceptable in a lot of applications. For example, it is not possible to use higher amounts of 
sodium salts in sweet beverages or sweeteners in savory applications. Therefore, the 
applicability of such compounds is only limited. 
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D. Drug Properties15-16 
For the ideal FDT technology, the drug properties should not significantly affect thetablet 
property. Many drug properties could potentially affect the performance ofFDTs. For 
example, the solubility, crystal morphology, particle size, hygroscopicity,compressibility, and 
bulk density of a drug can significantly affect the final tablet’scharacteristics, such as tablet 
strength and disintegration. The FDT technologyshould be versatile enough to accommodate 
unique properties of each drug .Several factors must be considered whenselecting drug 
candidates for delivery as ODTdosage forms. In general, an ODT isformulated as a 
bioequivalent line extension ofan existing oral dosage form. Under thiscircumstance, it is 
assumed that theabsorption of a drug molecule from the ODToccurs in the postgastric GIT 
segments,similar to the conventional oral dosage form.But this scenario may not always be 
the case.An ODT may have varying degrees ofpregastric absorption and thus, 
thepharmacokinetic profiles will vary.Therefore,the ODT will not be bioequivalent to 
theconventional oral dosage form. For example,ODT formulations of selegiline, 
apomorphine,and buspirone have significantly differentpharmacokinetic profiles compared 
with thesame dose administered in a conventionaldosage form. It is possible that these 
differences may, in part, be attributed to the drug molecule,formulation, or a combination of 
both. If significantly higher plasma levels have beenobserved, pregastric absorption leading 
to theavoidance of first-pass metabolism may playan important role. This situation may 
haveimplications for drug safety and efficacy,which may need to be addressed andassessed in 
a marketing application for anODT. 
For example, safety profiles may beimproved for drugs that produce a significantamount of 
toxic metabolites mediated by firstpassliver metabolism and gastric metabolismand for drugs 
that have a substantial fractionof absorption in the oral cavity and segmentsof the pregastric 
GIT.Drugs having ability to diffuse and partitioninto the epithelium of the upper GIT (log P > 
1,or preferable > 2); and those able to permeateoral mucosal tissue are considered ideal 
forODT formulations. Patients who concurrentlytake anticholinergic medications may not 
bethe best candidates for these drugs. Similarly,patients with Sjögren’s syndrome or 
drynessof the mouth due to decreased salivaproduction may not be good candidates for these 
tablet formulation.   Drugs which arevery bitter or otherwise unacceptable tastebecause taste 
masking cannot be achieved orthose which require controlled or sustainedrelease are 
unsuitable candidates of rapidlydissolving oral dosage forms.Researchers have formulated 
ODT for variouscategories of drugs used for therapy in whichrapid peak plasma 
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concentration is required toachieve the desired pharmacologicalresponse. These include 
neuroleptics,cardiovascular agents, analgesics, antiallergic,anti-epileptics. 
 
E. Tablet Strength and Porosity 
Because FDTs are designed to have a quick dissolution/disintegration time, thetablet porosity 
is usually maximized to ensure fast water absorption into the tablets. The key properties of 
the tablets are fast absorption or wetting of water into thetablets and disintegration of 
associated particles into individual components for fast dissolution. This requires that 
excipients should have high wettability, and the tabletstructure should also have a highly 
porous network. Because the strength of a tabletis related to compression pressure, and 
porosity is inversely related to compression pressure, it is important to find the porosity that 
allows fast water absorption whilemaintaining high mechanical strength. In addition, low 
compression pressure causes fast dissolving dosage forms to be soft, friable, and unsuitable 
for packaging inconventional blisters or bottles. A strategy to increase tablet mechanical 
strength without sacrificing tablet porosity or requiring a special packaging to handle 
fragiletablets should be provided. 
 
F. Moisture Sensitivity 
FDTs should have low sensitivity to humidity. This problem can be especially 
challengingbecause many highly water-soluble excipients are used in formulation toenhance 
fast dissolving properties as well as to create good mouth feel. Those highlywater-soluble 
excipients are susceptible to moisture; some will even deliquesce athigh humidity. A good 
package design or other strategy should be created to protectFDTs from various 
environmental conditions. 
 
G. Palatability 
As most drugs are unpalatable, orallydisintegrating drug delivery systems usuallycontain the 
medicament in a taste-maskedform. Delivery systems disintegrate ordissolve in patient’s oral 
cavity, thus releasingthe active ingredients which come in contactwith the taste buds; hence, 
taste-masking ofthe drugs becomes critical to patientcompliance. 
 
H. Amount of drug 
The application of technologies used for ODTsis limited by the amount of drug that can 
beincorporated into each unit dose. Forlyophilized dosage forms, the drug dose mustbe lower 
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than 400 mg for insoluble drugs andless than 60 mg for soluble drugs. Thisparameter is 
particularly challenging whenformulating a fast-dissolving oral films orwafers 
 
I. Aqueous solubility 
Water-soluble drugs pose various formulationchallenges because they form eutecticmixtures, 
which result in freezing-pointdepression and the formation of a glassy solidthat may collapse 
upon drying because of lossof supporting structure during the sublimation process. Such 
collapse sometimes can beprevented by using various matrix-formingexcipients such as 
mannitol than can inducecrystallinity and hence, impart rigidity to theamorphous composite 
. 
 
J. Size of tablet 
The degree of ease when taking a tabletdepends on its size. It has been reported thatthe 
easiest size of tablet to swallow is 7-8 mmwhile the easiest size to handle was onelarger than 
8 mm. Therefore, the tablet sizethat is both easy to take and easy to handle isdifficult to 
achieve. 
 
1.4. Approaches to ODT Development16-19 
The fast disintegrating property of the tablet isattributable to a quick ingress of water into the 
tablet matrix resulting in its rapiddisintegration. Hence, the basic approaches to develop 
rapidly dissolving oral dosage formsinclude maximizing the porous structure of thetablet 
matrix, incorporating the appropriatedisintegrating agent and using highly 
watersolubleexcipients in the formulation. As isoften the case, a technology that is 
originallydeveloped to address a particularadministration need can quickly become adopted 
as part of a pharmaceuticalcompany’s product life cycle managementstrategy, which is 
precisely what hashappened with ODT technologies. Severalpatented technologies with their 
basis offormulation are listed in Table.The technologies that have been used byvarious 
researchers to prepare orallydisintegrating dosage forms include4-6:  
 
1. Freeze-Drying or Lyophilization,  
2. Molding, 
3.Wet granulation followed by compression 
4. DirectCompression, 
5.Disintegrant addition, 
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6. Sublimation,  
7. Spray Drying,  
8. Mass Extrusion, 
9. Cotton-candy process,  
10. NanoCrystalTMTechnology, 
11. Oral films/wafer 
 
1.4.1Table3 ODT Patents 16-19 
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1.4.2 Table.4 ADVANTAGES AND DISADVANTAGES OF ODT 
TECHNOLOGIES16-19 
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     1.4.3Table.5. SOME OF THE MARKETED ODT FORMULATIONS 
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1.5. ADDITIVES USED IN ODT’S 32-35 
Various additives can be added to the formulation as long as they donot spoil the effects of 
present invention. They include 
1. Disintegrating agents 
2. Binding agents 
3. Souring agents 
4. Vesicants 
5. Artificial sweeteners 
6. Perfumes 
7. Lubricants 
8. coloring agents 
 
1.5.1 DISINTEGRANTS USED IN FDTS: 
Some patents use effervescent couples as their disintegrant, while others use a 
combinationofdisintegrants. Dobetti summarized different types of non-
effervescentdisintegrants used in the pharmaceutical area. 
• Starch and modified starches.This group includes natural starches (such as maize 
starch and potato starch), directly compressible starches (such as starch 1500), 
modified starches (such as carboxymethylstarches and sodium starch glycolate), 
and starch derivatives (such as amylose). 
• Cross-linked polyvinylpyrrolidone 
• Modified celluloses such as cross-linked sodium carboxymethylcellulose 
• Alginic acid and sodium alginate 
• Microcrystalline cellulose 
• Methacrylic acid-divinylbenzene copolymer salts 
1.5.2. Superdisintegrants: 19 
These are the agents added to tablet formulations to promote the breakup of tablet into 
smaller fragments in an aqueous environment there by increasing the available surface area 
and promoting a more rapid release of the drug substance.  
Ideal characteristics: 
 Should produce rapid disintegration 
 Compactable enough to produce less friable tablets 
 Effective at low concentration 
 Have greater disintegrating efficiency 
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 Mechanism of superdisintegrants: 
There are four major mechanisms for tablets disintegration as follows: 
1. Swelling: 
Perhaps the most widely accepted general mechanism of action for tablet 
disintegration is swelling. Tablets with high porosity show poor disintegration due to lack of 
adequate swelling force. On the other hand, sufficient swelling force is exerted in the tablet 
with low porosity. It is worthwhile to note that if the packing fraction is very high, fluid is 
unable to penetrate in the tablet and disintegration is again slows down. 
 
2. Porosity and capillary action (Wicking): 
Disintegration by capillary action is always the first step. When we put the tablet into 
suitable aqueous medium, the medium penetrates into the tablet and replaces the air adsorbed 
on the particles, which weakens the intermolecular bond and breaks the tablet into fine 
particles. Water uptake by tablet depends upon hydrophilicity of the drug/excipient and on 
tableting conditions. For these types of disintegrants maintenance of porous structure and low 
interfacial tension towards aqueous fluid is necessary which helps in disintegration by 
creating a hydrophilic network around the drug particles. 
 
 
Figure.03 - Disintegration of Tablet by Wicking and Swelling (Pharmainfo.net) 
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3. Due to disintegrating particle/particle repulsive forces 
Another mechanism of disintegration attempts to explain the swelling of tablet made 
with ‘nonswellable’ disintegrants. Guyot-Hermann has proposed a particle repulsion theory 
based on the observation that nonswelling particle also cause disintegration of tablets. The 
electric repulsive forces between particles are the mechanism of disintegration and water is 
required for it. Researchers found that repulsion is secondary to wicking. 
 
4. Due to deformation. 
During tablet compression, disintegrated particles get deformed and these deformed 
particles get into their normal structure when they come in contact with aqueous media or 
water. Occasionally, the swelling capacity of starch was improved when granules were 
extensively deformed during compression. This increase in size of the deformed particles 
produces a break up of the tablet. This may be a mechanism of starch and has only recently 
begun to be studied. 
 
 
              Figure 04 - Disintegration by Deformation and Repulsion (Pharmainfo.net) 
             
17 
 
  1.5.2. Table 6 : Various superdisintegrants and their mechanism 
Superdisintegrants 
 
Commercially 
available 
Grades 
Mechanism of 
action 
Special comment 
Crosslinked 
Cellulose 
Crosscarmellose® 
Ac-Di-Sol®, 
Nymcel ZSX® 
Primellose®, 
Solutab®, 
Vivasol®, L-HPC. 
Swells 4-8 folds in 
< 10 seconds. 
Swelling and 
wicking both. 
Swells in two 
dimensions. Direct 
compression or 
Granulation Starch 
free. 
Crosslinked PVP Crosspovidon M® 
Kollidon® 
Polyplasdone® 
Swells very little 
and returns to 
original size after 
compression but act 
by capillary action. 
Water insoluble and 
spongy in nature so 
get porous tablet. 
Crosslinked starch Explotab® 
Primogel® 
Swells 7-12 folds in 
< 30 
seconds. 
Swells in three 
dimensions and high 
level serve as 
sustain release 
matrix. 
Crosslinkedalginic 
Acid 
Alginic acidNF Rapid swelling in 
aqueous medium or 
wicking action. 
Promote 
disintegration in 
both dry or wet 
granulation. 
Soy polysaccharides Emcosoy®  Does not contain 
any starch or 
Sugar. Used in 
nutritional products. 
Calcium silicate  Wicking action. Highly porous, 
Light weight 
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1.5.3. Binding agents: 
Powdered acacia, gelatin, pullulanetc 
 1.5.4. Souring agents: 
Citric acid, tartaric acid, malic acid 
1.5.5. Vesicants 
Sodium bicarbonate 
 1.5.6. Artificial sweeteners 
Saccharin sodium, glycyrrhizin, aspartame, stevia, thaumatin. 
 1.5.7. Perfumes 
Lemon, lemon lime, orange, menthol 
 1.5.8. Lubricants 
Magnesium stearate, sucrose fatty acid esters, polyethylene glycol, talc, 
sodiumstearylfumarate 
1.5.9. Coloring agents 
Food dyes, Food Lake dyes, red iron oxide 
 
 
1.6 ODT Evaluation of Special Concern17-19 
Crushing strength and friability can beassessed as stated in pharmacopoeias. Butsome tests 
are of special concern and theseinclude the following: 
 
1.6.1 Wetting time 
Wetting time of dosage form is related to thecontact angle. It needs to be assessed to give 
an insight into the disintegration properties ofthe tablets; a lower wetting time implies a 
quicker disintegration of the tablet. For thispurpose, a tablet is placed on a piece of tissue 
paper folded twice and kept in a small Petridish (ID = 6.5 cm) containing 6 ml of water, 
and the time for complete wetting ismeasured. 
 
1.6.2 Disintegration test 
The time for disintegration of ODTs isgenerally less than one minute and actualdisintegration 
time that patient can experienceranges from 5-30 seconds. The standard procedure of 
performing disintegration test forthese dosage forms has several limitationsand they are not 
suitable for the measurementof very short disintegration times. The methodneeds to be 
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modified for ODTs asdisintegration is required without water; thusthe test should mimic 
disintegration in salivarycontents. A modified dissolution apparatus isapplied to an ODT with 
a disintegration timethat is too fast to distinguish differences between tablets when the 
compendial methodis used. A basket sinker containing the tabletsis placed just below the 
water surface in acontainer with 900 mL of water at 37 0C, and apaddle rotating at 100 rpm is 
used. Thedisintegration time is determined when thetablet has completely disintegrated 
andpassed through the screen of the sinker.Various scientistshave developed new 
invitromethods that allow an accuratedetermination of disintegration test. Thedisintegration 
test is performed using a textureanalyzer instrument. In this test, a flat-endedcylindrical probe 
penetrates into thedisintegrating tablet immersed in water. As thetablet disintegrates, the 
instrument is set tomaintain a small force for a determined periodof time. The plots of some 
distance traveledby the probe generated with the instrument’ssoftware provide disintegration 
profile of thetablets as a function of time. The plot facilitates calculation of the start and end-
pointof the tablet disintegration. 
 
1.6.3 Dissolution test  
The development of dissolution methods forODTs is comparable to the approach taken 
forConventional tablets, and is practicallyidentical. Dissolution conditions for drugslisted in a 
pharmacopoeia monograph, is agood place to start with scouting runs for abioequivalent 
ODT. Other media such as 0.1M HCl and buffer (pH 4.5 and 6.8) should beevaluated for 
ODT much in the same way astheir ordinary tablet counterparts.It has been suggested that 
USP 2 paddleapparatus is the most suitable and commonchoice for orally disintegrating 
tablets, with apaddle speed of 50 rpm commonly used. 
 
1.6.4 Moisture uptake studies  
Moisture uptake studies for ODT should beconducted to have an insight into the stabilityof 
the formulation, as several excipients usedare hygroscopic. Ten tablets from eachformulation 
are kept in a desiccator overcalcium chloride at 370C for 24 h. The tabletsare then weighed 
and exposed to 75% RH atroom temperature for two weeks. The requiredhumidity (75% RH) 
is achieved by keepingsaturated sodium chloride solution at thebottom of the desiccator for 
three days. Onetablet as control (without superdisintegrant) iskept to assess the moisture 
uptake due toother excipients. Tablets are weighed and thepercentage increase in weight is 
recorded 
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1.6.5. Fitness of Dispersion 
This is a qualitative test specified by EP for ODTs.It is an assessment of the grittiness which 
arises due to disintegration of the tablet in to coarse particles.The test is performed by placing 
two tablets in 100ml water and stirring it gently,till the tablets get completely 
disintegrated.The formulation is considered to form a smooth dispersion if the complete 
dispersion passes through a sieve screen with a nominal mesh aperture of 710 microns with 
out leaving any residue on the mesh. 
 
1.7. Packaging of ODT 
Packing is one of the important aspects in manufacturing ODT. The products obtained by 
various technologies vary in some of the parameters especially in mechanical strength to a 
good extent. The products obtained by lyophilization process including various technologies 
such hasZydis, Lyoc, Quicksolv, and Nanocrystal are porous in nature, have less physical 
resistance, sensitive to moisture, and may degrade at higher humidity conditions. For these 
reasons products obtained require special packing. Zydis units are generally packed with 
peelable backing foil. Paksolv is a special packaging unit, which has a dome-shaped blister, 
which prevents vertical movement of tablet with in the depression and protect tablets from 
breaking during storage and transport, which is used for Orasolv tablet. Some of the products 
obtained from Durasolv. WOW Tab, Pharmaburstoraquick, Ziplets, etc. technologies have 
sufficient mechanical strength to withstand transport and handling shock so they are generally 
packed in push through blisters or in bottles. 
 
1.8.Patient counseling in effective use of ODT29 
ODT developed offers significant advantages for various group of patients, but the majority 
of patients receiving ODT have little understanding of this novel dosage form. Patients 
receiving ODT may be surprised when tablets begin to disintegrate/dissolve in mouth. As 
pharmacists are ideal persons to know about the recent technologies, thus have opportunity to 
educate the patients for effective treatment. 
Counseling of patients about this dosage form can avoid any confusion and misunderstanding 
in taking ODT. Patient information that needs to be provided include: 
 Storage of this dosage form as some of ODT developed may not have sufficient 
mechanical strength, which needs to be handled carefully.  
 Patients with Siogren's syndrome or dryness of mouth or who take anticholinergic 
drugs may not be suitable candidates for administering ODT. Although no water is 
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required to allow drug to disperse quickly and efficiently but decreased volume of 
saliva may slow the rate of disintegration/dissolution and may reduce the 
bioavailability of the product.  
 Patients need to be clearly told about the difference between effervescent and ODT. 
Some of technologies use effervescence, which experience a pleasing tingling effect 
on the tongue.  
 Although chewable tablets are available in market and patient need to be counseled 
about differences between chewable and ODT tablets. This ODT can be used easily in 
children who have lost their primary teeth and in geriatric patients who have lost their 
teeth permanently 
 With the pharmacists counseling, intervention and assistance about ODT, all patients 
receiving this novel dosage form could be more properly and effectively treated with 
greater convenience. 
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II. LITERATURE REVIEW 
 
 GawandeShilpa et.al,2011. was aimed towards the formulation and in vitro evaluation 
of orodispersibletablets by direct compression method using Risperidone as a model 
drug to enhance patientcompliance by masking the bitter taste of drug using cetyl 
alcohol in different ratios. Here crosspovidone andsodium starch glycolate in different 
concentrations (2%, 4%, 6% and 8%) are used assuperdisintegrant. All the batches 
were prepared by direct compression method andtablets were evaluated for weight 
variation, hardness, friability, in vitro disintegration time, invivo disintegration time, 
dispersion time, thickness, drug content and dissolution study. By considering 
disintegration time and concentration of superdisintegrant, formulation with drug to 
cetyl alcohol concentration (2:1) and crosspovidone 4% was optimised. Optimised 
tablet formulation was subjected to stability studies for three months at room 
temperature and 40c/75% RH. 
 
 Harshavardanguptha.K,et al.  FormulatedIt malate immediate release  oral dosage 
forms, i.e., tablets and capsules, are most widely used drug delivery systemsavailable. 
These products are designed to disintegrate in the stomach followed by 
theirdissolution in the fluids of the GIT.Microcrystalline cellulose, Galen IQ and 
Dicalciumphosphate were used as directly compressible fillers. In order to obtain 
acceptableproduct several trials were conducted. Various pharmacopoeial evaluations 
of theformulations were conducted including weight variation, hardness, 
disintegration time,friability and in-vitro dissolution. Final selection of formulation 
was done based onpharmaceutical equivalence of development formulation to that of 
marketed one.Theimmediate release of the medicament is achieved by the inclusion of 
the super-disintegrating agents such as sodium starch glycolate, cross carmellose 
sodium, crosspovidone 
 
 Shaikh.Siraj et al,2011. Formulated FDTs of Aceclofenac using different 
concentrations of superdisintegrants like sodiumstarchglycolate together with 
polyplasdoneXL10  prepared by wetgranulation technique followed by 
compression..Tabletswereevaluatedforweightvariation,Hardness,friability,Disintegrati
ontime,wettingtime,Dispersiontime.All formulations show iowweightvariation and 
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dispersion time  less than90seconds.The optimized formulation showed good drug 
release profile at all timeintervals.It was concluded that  improved aceclofenac  
dissolution was achieved with wet granulation technique. 
 
 Bhupendra G.Prajapati et al,2010.prepared fast dissolving tablets of Domperidone 
by wet granulation using Sodium Starch Glycolate as super disintegrant and starch 
paste as a binder. The disintegrant incorporated during the wet granulation process as 
extragranular incorporation. A32full factorial design was applied to investigate the 
combined effect of 2 formulation variables:Superdisintegrants and starch paste. Here 
the concentration of Superdisintegrants and concentration of starch paste were taken 
as independent variables. The effect of Disintegration time, wetting time, Q30 and 
friability were taken as dependent parameters. The optimized batch obtained from the 
factorial design was compared withthe marketed products. The stability study of the 
optimized batch is also done at 40 C and 75%RH 
 
 Venkataramanareddy S et.al,2010.  Developed oral disintegrating tablets 
(ODT) ofinsoluble and low bitter drugs like zaleplon using tasteenhancers as a taste 
masking agents. ODT of zaleplon were prepared using different superdisintegrants by 
direct compression method. Mannitolwas used as a diluent and sodium lauryl sulphate 
was used as a wetting (surfactant) agent. Aspartame and Acesulfame Potassium were 
used forunpleasant taste masked from the zaleplon by cosifting and serial of blending 
with otherexcipients. The mixed final blend was then compressedinto tablets. The 
formulations were evaluated for weight variation, hardness, friability, wetting time, 
disintegrating time, dissolution, taste evolutionstudy and in vitro dissolution. All the 
formulation showed low weight variation with different disintegration time and rapid 
in vitro dissolution. Theresults revealed that the tablets containing taste enhancers had 
a good palatability for the patients. 
 
 Khan et al, 2007. Have masked masked the intensely bitter taste of ondansetronHCl. 
Tastemasking was done by complexingondansetronHCl withaminoalkyl methacrylate 
copolymer (Eudragit EPO) indifferent ratios by the precipitation method. Drug-
polymercomplexes (DPCs) were tested for drug content, in vitrotaste in simulated 
salivary fluid (SSF) of pH 6.2, and molecularproperty.The complex with drug-
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polymer ratio of 8:2 did not show drug release in SSF; therefore, it was selected as an 
optimized ratio. 
 
 DebjitBhowmikTelmisartan is an Anti-hypertensive drug which is insoluble in water, 
hence the drug may be slowly orincompletely dissolves in the gastro-intestinal tract. 
So the rate of dissolution and therefore itsbioavailability is less (bioavailability 42%). 
He preparedFast Dissolving tablets of Telmisartan by using Superdisintegrants–
Crosspovidone, Ac-de-sol, and sodiumstarch glycolate, level of addition to increase 
the rate of drug release from dosage form to increase thedissolution rate and hence its 
bioavailability. The tablets were prepared by Direct Compression methodsand the 
prepared blend and tablets were evaluated for their physicochemical properties and 
In-Vitrodissolution study. The evaluation study were performed such as Weight 
Variation, Thickness, Hardness,Disintegrating Time, Wetting Time, and In-Vitro 
Drug Release and Stability Study. The Disintegration timeof Fast Dissolving tablets 
were increased by the addition of concentration of Superdisintegrants. 
 
 D.M.Patel et al Developed fast dissolving tablets of etoricoxib. Granules containing 
etoricoxib, menthol, crospovidone, aspartame and mannitol were prepared by wet 
granulation technique. Menthol was sublimed from the granules by exposing the 
granules to vacuum. The porous granules were then compressed in to tablets. 
Alternatively, tablets were first prepared and later exposed to vacuum. The tablets 
were evaluated for percentage friability and disintegration time. A 32 full factorial 
design was applied to investigate the combined effect of 2 formulation variables: 
amount of menthol and crospovidone. The results of multiple regression analysis 
indicated that for obtaining fast dissolving tablets; optimum amount of menthol and 
higher percentage of crospovidone should be   used. Sublimation of menthol from 
tablets resulted in rapid disintegration as       compared with the tablets prepared from 
granules that were exposed to vacuum. The optimized tablet formulation was 
compared with conventional marketed tablets for percentage drug dissolved in 30 min 
(Q30) and dissolution efficiency after 30 min (DE30). From the results, it was 
concluded that fast dissolving tablets with improved. 
 
 Mizumoto T et al., (1996);Formulation design of a novel 
fastdisintegratingtablet.Intrabuccally dissolving compressed moldings comprising a 
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saccharide US 5576014 etoricoxib dissolution could be prepared by sublimation of 
tablets containing suitable subliming agent. 
 
 Andries. F. Maris et al., (2003); were studied the effect of compression force, 
humidity and disintegrant concentration on disintegration and dissolution of 
furosemide tablets. 
 
 Late SG et al., has done research on effect of disintegration promoting agent, 
lubricants and moisture treatment on optimized fast disintegration tablets  
 
 Chowhan ZT(1980) has studied the effect of low and high humidity ageing on the 
hardness, disintegration time and dissolution rate of Dibasic calcium phosphate based 
tablets 
 
 Yourong Fu et al., (2004); Critical Reviews in Orally Fast Disintegrating Tablet   
Developments, Technologies,Taste-Masking and Clinical Studies. 
 
 Jaysukh J Hirani et al., (2009); Orally Disintegrating Tablets: A Review 
 
 Suresh Bandari et al., Orodispersible tablets- An overview 
 
 Mashru et al, 2008.  Used soliddispersion technique to mask the intensely bitter taste 
of artemether, an antimalerial drug and to improve its dissolution.Glycyrrhizin, which 
is also known as glycyrrhizinic (GLY) acid,is an oleanane-type triterpene glycoside 
which was used as a sweeteners was used to mask the bitter taste of drug in solid 
dispersion method.The solid dispersion of ARM and GLY in 1:0.5 and 1:1Mwas 
carried out using solvent evaporation method. Solid dispersion was characterized by 
solubility study, DSC, XRD and FTIR 
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III. NEED AND OBJECTIVE 
Migraine28-29 is a chronic neurological disorder characterized by moderate to severe 
headaches, and nausea. It is about three times more common in women than in men.The word 
derives from the Greekἡμικρανία (hemikrania), "pain on one side of the head",fromἡμι- 
(hemi-), "half", and κρανίον (kranion), "skull".The typical migraine headache is unilateral 
(affecting one half of the head) and pulsating in nature and lasting from two to 72 
hours.Initial treatment is with analgesics for the headache, an antiemetic for the nausea, and 
the avoidance of triggers. The cause of migraine headache is unknown; the most supported 
theory is that it is related to hyperexcitability of the cerebral cortex and/or abnormal control 
of pain neurons in the trigeminal nucleus of the brainstem 
 
3.1. Causes of Migraine Headache 
 
The main cause of migraine headache is the enlargement of temporal artery found just under 
the skin of the temples. It causes nerves to stretch around the temporal artery that in turn 
triggers the release of chemicals causing inflammation, pain and even more dilation of the 
artery. 
 Estrogen levels- Estrogen, mainly a female hormone, is also a cause of migraine 
headache. Therefore, more women than men experience migraines. Migraines caused 
to women due to estrogen occur just before, during, or after a menstrual period.  
 Stress- Mental and physical tension, consistent overwork, sleep disorders or too 
little/too much sleep, fatigue, all can cause migraine headache.  
 Caffeine- Excessive tea and coffee and even smoking and alcohol intake can cause 
migraine headaches. 
 Birth control pills- It is self explanatory as to why they are one of the causes of 
migraines as they affect the estrogen levels in women.  
  Nutritional deficiency- certain vitamins and other nutritional supplements are 
required to prevent inflammation and for proper working of muscles, veins etc. Not 
taking proper amount of nutrients or fasting for an extended period of time can thus 
cause migraine headache.  
  Heredity- Many victims have a "migraine gene" that predisposes them to migraine 
attacks.  
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3.2. Symptoms of Migraine Headache 
About 20% of migraine headache sufferers get visual warning before a migraine attack. They 
may see a kind of "aura" that may include flickering points of light, blind spots, or zig-
zagging lines. 
 Moderate to severe, throbbing headache- right side or left side of the head.  
  Head pain that gets severe with increased physical activity.  
 Sensitivity to light and/or sound.  
 Nausea or vomiting.  
 Red eyes with burning sensation in eyes  
 Loss of appetite  
  Migraine sufferer wants to stay all alone and finds comfort in silent and dark room  
  Depression and irritability  
  Numbness or weakness in an arm or leg . 
 
In recent years, the importance of patient compliance,not only in drug efficacy  but also in 
overall economicsof healthcare, has been increasingly recognized. Efforts toimprove patient 
compliance have included attempts toimprove the palatability of orally administered 
pharmaceuticalagents especially for children and elderly. Inparticular, a bitter taste is known 
to decrease patientcompliance, and thus reduce effective pharmacotherapy.Various 
techniques are used to mask the bitter taste of drug.  
In the present work, model drug is a moderately bitter drug,an attempt has been made 
to mask the taste of modeldrug by using sweetners like aspartame and mannitol in the 
formulation.  
The literature survey revealed that no work has been reported on ODT of the modeldrug 
 
3.3. OBJECTIVE: 
 
The main objective is to formulate ODT’S  by using different superdisintegrants and 
sweetners in different ratio’s and evaluating its characteristics in order to improve the release 
rate,disintegration time,  tastemasking and also providing better patient compliance. 
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IV.PLAN OF WORK 
 
4.1. Model drug and excipients profile 
 
4.2. Procurement of drug, and excipients 
 
4.3. Preformulation study 
 Solubility studies 
 Calibration curve of model drug 
 Drug excipients interaction study 
       Differential scanning calorimetry 
 Characterisation of API 
 
4.4. Formulation of Tablets 
 Selection of drug-excipients ratio 
 Preparation of binder solution 
 Wet granulation 
Compression      
Optimization of composition 
a) Trial with different disintegrant 
b) Trial with different concentration of excipients 
Process optimization 
               Hardness challenge study 
 
4.5. Evaluation of compressed tablets 
Precompression parameters 
             Flow Properties (Angle of repose and Compressibility index) 
             Particle size distribution by dry sieve analysis 
Postcompression parameters 
o Weightvariation 
o Hardness 
o Thickness 
o %Friability 
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o Disintegration time 
o Wetting time 
o Moisture uptake studies 
o Fitness of dispersion 
o Taste evaluation 
4.6 . XRD Analysis of final formulation 
 
4.7. FTIR study of final formulation 
 
4.8. Stability study of optimized formulation 
 
4.9. Invitro Drug Release studies 
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V.MODEL DRUG PROFILE 28-29 
 
Physicochemical parameters 
Structure 
 
 
IUPAC Name 
1-[[[3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl]methyl]sulfonyl]pyrrolidine (±)-
hydroxybutanedioate. 
Empiricalformula :    C17H25N3O2S-C4H6O5 
Molecular Weight   :   469.56 
Category                  :  Anti-migraine agent  
Description               :It is a white to slightly yellow crystalline powder  
Melting point            :167-1730C 
Solubility                    :Freely soluble in water and methanol but practically insoluble in 
ethanol and methylene chloride. 
Mechanism of action 
 Modeldrugselectively binds with high affinity to 5–hydroxytryptaminergic receptors 
(5–HT 1D, 5–HT1B and 5–HT1F). It has weak affinity for 5–HT1A and 5–HT7 receptors, but has 
no significant affinity or pharmacological activity at 5–HT2, 5–HT3, 5–HT4 or 5–HT-6 
receptors. It has been proposed that migraine symptoms are due to local cranial vasodilatation 
and/or to the release of pro-inflammatory and vasoactive neuropeptides from the trigeminal 
nerve endings. most likely acts on the 5–HT1B/1D receptors on the extracerebral, intracranial 
dilated blood vessels during a migraine attack, and on nerve terminals in the trigeminal 
system resulting in cranial vessel constriction, inhibition of neuropeptide release, and reduced 
transmission in trigeminal pain pathways 
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PHARMACOKINETICS 
Absorption: 
It is well absorbed after oral administration (absolute bioavailability about 70%). The rate and 
extent of absorption are not affected by administration with food. 
Distribution: 
The mean apparent volume of distribution is 180 to 200 liters 
Protein binding: 
Low (approximately 35%). 
Biotransformation: 
It is metabolized by one minor and two major pathways. Monoamine oxidase (MAO)-
mediated oxidative deamination (approximately 27% of the dose), and cytochrome P450–
mediated oxidation (approximately 12% of the dose) are the major routes of metabolism, 
while flavin monooxygenase is the minor route 
Half-life: 
3 to 4 hours. 
Time to peak concentration: 
Oral— 1 to 3 hours after administration 
Elimination: 
    Renal; it is eliminated primarily by renal excretion (about 75% of the oral dose). 
Approximately 40% of an administered dose is excreted unchanged in uriine.    Fecal; 
approximately 13% of the administered dose is excreted via feces, both unchanged and 
metabolized. 
Usual adult dose 
Oral, 6.25 or 12.5 mg (base) as a single dose. If necessary, an additional dose may be taken 
after two hours 
Indications 
Model drug  is intended for the acute treatment of migraine with or without aura in adults. 
Contraindications 
It is contraindicated in patients with history,signs or symptoms of ischemic 
cardiac,cerebrovascular and peripheral vascular syndromes,valvular heart disease 
orcardiacarrythmias especially tachycardias. 
 
Side effects 
 mild headache (not a migraine). 
 dry mouth, mild nausea. 
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 feeling of pain or tightness in your jaw, neck, or throat;  
 pressure or heavy feeling in any part of your body. 
 dizziness, drowsiness, weakness and 
 mild tingly feeling.  
 
DRUG INTERACTIONS 
Ergot-Containing Drugs 
These drugs have been reported to cause prolonged vasospastic reactions. Because there is a 
theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-
type medications (like dihydroergotamine or methysergide) and it malate within 24 hours of 
each other should be avoided.  
 
Monoamine Oxidase Inhibitors 
Co administration of moclobemide resulted in a 27% decrease in it clearance and an increase 
in Cmaxof approximately 6%. No dose adjustment is necessary.  
 
Propranolol 
The pharmacokinetics of it were not affected by co administration of propranolol 
 
Storage 
Store at 25°C (77°F); excursions permitted between 15 and 30 °C (59 and 86 °F). 
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VI. EXCIPIENT PROFILE25 
 
6.1.Mannitol 
Structural Formula 
 
 
Table.7 Profile ofMannitol 
 
Nonproprietary Names • BP: Mannitol 
• JP: D-Mannitol 
• PhEur: Mannitolum 
• USP: Mannitol 
 
 
Synonyms 
 
Cordycepicacid,manna sugar; D-mannite; 
mannite; Mannogem,Pearlitol 
Chemical Name and CAS Registry Number D-Mannitol [69-65-8] 
 
Empirical Formula C6H14O6 
Molecular Weight 182.17 
 
Functional Category Diluent; diluent for lyphilized preparations; 
sweetening agent; tablet and capsule 
diluent, tonicity agent. 
 
Description occurs as a white, odorless, crystalline 
powder, or free-flowing granules. It has 
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asweet taste, and imparts acooling 
sensation in the mouth. 
Density 1.514 g/cm3 
 
Melting point: 
 
166–168°C 
 
Solubility  
Stability and Storage The bulk material should be stored in a 
well-closed container in a cool, dry place. 
 
Incompatibilities 
 
 
 
 
 
Handling precautions 
 
Mannitol is incompatible with xylitol 
infusion and may form complexes with 
some metals such as aluminum, copper, 
and iron. 
 
 Mannitol may be irritant to the eyes; eye 
protection is recommended 
Applications Used as a diluent (10–90% w/w) in tablet 
formulations, Mannitol may be used in 
direct-compression tablet applications,for 
which the granular and spray-dried forms 
are available. 
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6.2. Aspartame 
Structural Formula  
 
 
 
Table.8 Profile ofAspartame 
 
Nonproprietary Names • BP: Aspartame 
• PhEur: Aspartamum 
• USPNF: Aspartame 
 
Synonyms 
 
aspartyl phenylamine methyl ester; 
Canderel;Equal; methyl N-α-L-aspartyl-L-
phenylalaninate; NutraSweet; Pal Sweet; 
Pal Sweet Diet; Sanecta; Tri-Sweet. 
Chemical Name and CAS Registry Number N-α-L-Aspartyl-L-phenylalanine 1-methyl 
ester [22839-47-0] 
 
Empirical Formula   C14H18N2O5 
Molecular Weight 
 
294.31 
 
Functional Category 
. 
Sweetening agent 
Description 
 
Aspartame occurs as an off white, almost 
odorless crystalline powder with an 
intensely sweet taste 
Density  
 
1.347 g/cm3 
 
Melting point 
 
246–247°C 
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Solubility 
. 
slightly soluble in ethanol (95%); sparingly 
soluble in water 
Stability and Storage The bulk material should be stored in a 
well-closed container, in a cool, dry place 
 
Incompatibilities 
 
aspartame is incompatible with dibasic 
calcium phosphate and also with the 
lubricant magnesium stearate 
Handling Precautions 
. 
Measures should be taken to minimize the 
potential for dust explosion. Eyeprotection 
is    recommended 
Applications Aspartame is used as an intense sweetening 
agent in beverage products, food products, 
andtable-top sweeteners. Therapeutically, 
aspartame has also been used in the 
treatment of sickle cell anemia. 
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6.3. POLYPLASDONE XL -10 
Table.9 Profile of Polyplasdone xl-10 
 
Nonproprietary Names • BP: Crospovidone 
• PhEur: Crospovidonum 
• USPNF: Crospovidone 
Synonyms Crospovidone, Polyvinylpyrrolidone. 
Molecular weight about 45,000 daltons 
Description 
 
Non-ionic, crosslinked, White, free 
flowing, compressible powder 
pH(10 %slurry) 
 
5.0 – 8.0 
Composition 
 
A synthetic homopolymer of cross-linked 
N-vinyl-2-pyrrolidone. 
Functional categories Disintegrant, Solubilizer 
Solubility 
Completely insoluble in water, acids, 
alkalis, and all organic solvents. 
Hygroscopic. Swells rapidly in water. 
Rapidly disperses in water, but does not gel 
even after prolonged exposure. 
Melting point Not available 
Stability and storage conditions 
 
Store in cool place. Keep container tightly 
closed in a dry and well-ventilated place. 
Provide appropriate exhaust ventilation at 
places where dust is formed.Normal 
measures for preventive fire protection. 
Incompatibilities Strong oxidizing agents. 
Applications 
Super disintegrant and dissolution aid in 
wet granulation, dry granulation and direct 
compression. 
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6.4. Hydroxypropyl Cellulose(Klucel EXF) 
 
 Structural Formula 
 
 
 
Table.10 Profile of Klucelexf 
 
Nonproprietary Names 
 
• BP: Hydroxypropylcellulose 
• JP: Hydroxypropylcellulose 
• PhEur: Hydroxypropylcellulosum 
• USPNF: Hydroxypropyl cellulose 
Synonyms Cellulose, 2-hydroxypropyl ether; 
oxypropylated cellulose. 
Molecular weight Variable 
Description 
 
 White, free flowing, compressible powder 
Viscosity 
 
Lowest viscosity, varies based on the 
specific use 
Composition 
 
Nisso HPC consists of hydroxypropyl 
ethers obtained by the reaction of cellulose 
with propylene oxide. 
Functional categories 
It is used as a topical ophthalmic protectant 
and lubricant. 
Solubility Soluble in both water and organic solvents. 
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Melting point Variable 
Stability and storage conditions 
 
Store in cool place. Keep container tightly 
closed in a dry and well-ventilated place. 
Provide appropriate exhaust ventilation at 
places where dust is formed.Normal 
measures for preventive fire protection. 
Incompatibilities Strong oxidizing agents. 
Applications 
available for food use as a fat substitute, 
whipping aid, emulsion aid, and for film 
coating and tablet binding.  
 
 
 
6.5. Cellulose, Microcrystalline 
Structural Formula 
 
 
Table.11 Profile of Microcrystalline cellulose 
 
Nonproprietary Names 
 
• BP: Microcrystalline cellulose 
• JP: Microcrystalline cellulose 
• PhEur: Cellulosummicrocristallinum 
• USPNF: Microcrystalline cellulose 
 Synonyms 
 
Avicel PH; Celex; cellulose gel; Celphere; 
Ceolus KG; crystalline cellulose; E460; 
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Emcocel; Ethispheres; Fibrocel; 
Pharmacel; Tabulose; Vivapur 
Chemical Name and CAS Registry Number 
Empirical Formula and Molecular Weight 
Cellulose [9004-34-6.] 
 Functional Category 
 
Adsorbent; suspending agent; tablet and 
capsule diluent; tablet disintegrant 
Description 
 
Microcrystalline cellulose is a purified, 
partially depolymerized cellulose that 
occurs as awhite, odorless, tasteless, 
crystalline powder composed of porous 
particles. It iscommercially available in 
different particle sizes and moisture grades 
that have differentproperties and 
applications. 
Density  
 
1.512–1.668 g/cm3 
 
Melting point 
 
260–270°C. 
 
Solubility 
 
slightly soluble in 5% w/v sodium 
hydroxide solution; practically insoluble in 
water, dilute acids, and most organic 
solvents 
Stability and Storage Conditions 
 
Microcrystalline cellulose is a stable 
though hygroscopic material. The bulk 
material should be stored in a well-closed 
container in a cool, dry place 
 Incompatibilities 
 
Microcrystalline cellulose is incompatible 
with strong oxidizing agents 
Handling Precautions 
 
Microcrystalline cellulose may be irritant 
to the eyes. Gloves, eye protection, and a 
dust mask are recommended 
Applications Microcrystalline cellulose is widely used in 
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pharmaceuticals,primarily as a 
binder/diluent inoral tablet and capsule 
formulations where it is used in both wet-
granulation and directcompression. 
 
 
 
6.6. Sodium StearylFumarate 
 
Structural formula 
 
 
Table.12 Profile of Sodiumstearylfumarate 
 
 Nonproprietary Names BP: Sodium stearyl fumarate 
PhEur: Natriistearylisfumaras 
USPNF: Sodium stearylfumarate 
 Synonyms 
 
Fumaric acid, octadecylester,sodium mono 
stearyl fumarate 
Chemical Name and CAS Registry 
Number 
 
2-Butenedioic acid, monooctadecyl ester, 
sodium salt [4070-80-8] 
 Empirical Formula  
 
C22H39NaO4  
 
Molecular weight 390.5 
Functional Category 
 
Tablet and capsule lubricant 
 Description Sodium stearylfumarate is a fine, white 
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powder with agglomerates of flat, circular-
shaped particles 
Density 
 
1.107 g/cm3 
 
Melting point 
 
224–245°C 
Solubility 
 
Practically insoluble in acetone, 
chloroform,and slightly soluble in 
methanol. 
Stability and Storage The bulk material should be stored in a 
well-closed container in a cool, dry place. 
Incompatibilities 
 
Sodium stearylfumarate is reported to be 
incompatible with chlorhexidine acetate 
Handling Precautions 
. 
 
 
Sodium stearylfumarate should be handled 
in a well-ventilated environment; eye  
 protection is recommended. 
 
 
Applications Sodium stearylfumarate is used as a 
lubricant in capsule and tablet formulations 
at 0.5–2.0% w/w concentration. It is also 
used in certain food applications. 
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6.7.Sodium Starch Glycolate 
 
 
 
 
Table.13 Profile of Sodium starch glycolate 
 
Nonproprietary Names 
 
• BP: Sodium starch glycollate 
• PhEur: Carboxy methyl amylumnatricum 
• USPNF: Sodium starch glycolate 
Synonyms 
 
Carboxymethyl starch, sodium salt; 
Explosol; Explotab; Glycolys; Primojel, 
carboxymethyl ether, sodium salt; Tablo; 
Vivastar P. 
Chemical Name and CAS Registry 
Number 
 
Sodium carboxymethyl starch [9063-38-1] 
Functional Category Tablet and capsule disintegrant. 
Description 
 
Sodium starch glycolate is a white to off-
white, odorless, tasteless, free-flowing 
powder 
Density (true): 
 
1.443 g/cm3; 
Melting point: 
 
does not melt, but chars at approximately 
200°C. 
Solubility sparingly soluble in ethanol (95%); 
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. practically insoluble in water 
Stability and Storage Sodium starch glycolate is stable and 
should be stored in a well-closed container. 
Incompatibilities 
 
Sodium starch glycolate is incompatible 
with ascorbic acid 
Handling Precautions 
 
 Sodium starch glycolate may be irritant to 
the eyes; eye protection and gloves are 
recommended. 
Applications as a disintegrant in capsule 
and tablet formulations.It is commonly 
used in tablets prepared by either direct 
compressionor wet-granulation processes. 
 
6.8. Croscarmellose Sodium 
 
Table.14 Profile of Croscarmellose sodium 
 
Nonproprietary Names 
 
BP: Croscarmellose sodium 
PhEur: Carmellosumnatricumconexum 
USPNF: Croscarmellose sodium 
Synonyms 
. 
Ac-Di-Sol; 
crosslinkedcarboxymethylcellulose 
sodium; Explocel; modified cellulose 
gum;Nymcel ZSX; Pharmacel XL; 
Primellose; Solutab; Vivasol 
Chemical Name and CAS Registry 
Number 
 
Cellulose, carboxymethyl ether, sodium 
salt, crosslinked [74811-65-7] 
Molecular Weight 90 000–700 000. 
Functional Category 
 
Tablet and capsule disintegrant 
Description 
 
Croscarmellose sodium occurs as an 
odorless, white or grayish-white powder 
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Density  
 
1.543 g/cm3 
Solubility: 
 
insoluble in water, although croscarmellose 
sodium rapidly swells to 4–8 times its 
original volume on contact with water. 
Practically insoluble in acetone, ethanol 
and toluene 
Stability and Storage Croscarmellose sodium should be stored in 
a well-closed container in a cool, dry place 
Incompatibilities Croscarmellose sodium is not compatible 
with strong acids or with soluble salts of 
iron and some other metals such as 
aluminum, mercury, and zinc. 
Handling Precautions 
. 
Croscarmellose sodium may be irritant to 
the eyes; eye protection is recommended 
Applications Croscarmellose sodium is used in oral 
pharmaceutical formulations as a 
disintegrant for capsules,tablets,and 
granules. 
 
6.9. Colloidal Silicon Dioxide 
Table.15 Profile of colloidalsilicon dioxide 
 
Nonproprietary Names 
 
BP: Colloidal anhydrous silica 
PhEur: Silica colloidalisanhydrica 
USPNF: Colloidal silicon dioxide 
Synonyms 
 
Aerosil; Cab-O-Sil;  colloidal silica; fumed 
silica; light anhydrous silicic acid; silicic 
anhydride; silicon dioxide fumed 
Chemical Name and CAS Registry 
Number 
 
Silica [7631-86-9] 
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Empirical Formula  
 
SiO2 
Molecular Weight 60.08 
Functional Category 
. 
Adsorbent; anticaking agent; emulsion 
stabilizer; glidant; suspending agent; tablet 
disintegrant; thermal stabilizer; viscosity-
increasing agent 
Description 
 
 It is a light, loose, bluish-white-colored, 
odorless, tasteless, nongritty amorphous 
powder. 
Solubility practically insoluble in organic solvents, 
water, and acids, except hydrofluoric acid; 
soluble in hot solutions of alkali hydroxide. 
Forms a colloidal dispersion with water. 
Stability and Storage Colloidal silicon dioxide is hygroscopic. It 
should be stored in a well-closed container 
Incompatibilities 
 
Incompatible with diethylstilbestrol 
preparations 
Handling Precautions Eye protection and gloves are 
recommended For larger quantities, a dust 
respirator is recommended.. 
Applications Colloidal silicon dioxide is also used to 
stabilize emulsions and as a thixotropic 
thickening and suspending agent in gels  
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VII. MATERIALS 
 
The following drug, excipients and chemicals were used for the formulation and evaluation of  
orodispersible tablets 
.Table.16.List of chemicals and excipients 
 
Sr.No 
 
Excipient Supplier 
1 API 
 
Mylan laboratories Ltd 
2 Aspartame 
 
The Nutra Sweet Company 
3 Microcrystalline cellulose 
 
Sri International 
4 Polyplasdone xl-10 
 
A.B.Enterprises 
5 Sodium starch glycolate 
 
Healthy life pharma pvt Ltd 
6 Croscarmellose sodium 
 
Alpha chemika 
7 Kyron T-314 
 
Corel pharma 
8 Klucel EXF 
 
Industrial chemicals pvt Ltd 
9 Sodium stearylfumarate 
 
BCM Corporation 
10 Colloidal silicon dioxide 
 
H.D.Pharmachem 
11 Mannitol 
 
Taj Pharma 
12 Peppermint flavour 
 
TriveniInterchempvt Ltd 
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VIII. EQUIPMENTS 
 
Table.17. LIST OF EQUIPMENTS USED 
 
S.No. Name of  the Equipment Model Supplier 
1 Mechanical stirrer RZR 2102 control 
 
2.  Electronic weighing balance BBA422-3SM 
USA 
3. Disintegration Test apparatus ED-2AL  
4. Friabilator EF/W 
 
5. Laboratory oven DTC-00R 
 
6. Compression machine CMD4 
 
7. Stability chamber - 
 
8. Tablet hardness tester Tablet tester 8M 
 
9. 
Induction cap sealear CsP 300 
 
10. UV-Shimadzu UV-2450  
11. Quadraco mill 197 S  
12. 
Sieves - 
 
13. 
DSC 822 e 
 
14. 
XRD  
 
15. 
FTIR Spectrum 
 
16. Dissolution apparatus TDT-08L 
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IX. PREFORMULATION STUDY 
 
Drug Analysis 
9.1.Solubility studies26 
Solubility study of Model drug  in different media: 
Solubility studies were performed by taking required quantity  of  drug in 10 mL of different  
buffersat various pH conditions (pH 1.2, pH 4.5acetate, pH 6.8phosphate buffer,  and water) 
separately up to its saturation and subjected to mechanical shaking at 100 rpm for 24 hrs. The 
resultant dispersions were collected and filtered through 0.2 µ filters and the concentration of 
drug was determined from absorbance at 227 nm.  
 
 9.2.Determination of λmax 
Procedure:  
100mg of pure drug was taken and known concentration of drug solution was prepared by 
solubilizing in 0.1NHCL and it was scanned from 200-400 nm against the  blank to fix 
absorption maxima. Spectrum of the model drug was obtained and λmaxof model drug was 
found to be 227 nm. Hence all further investigations were carried out at the same wavelength. 
 
Calibration Curve of model drug in 0.1N HCl 
10 mg of model drug was dissolved in 100 ml of 0.1N HCl (PH1.2)to obtain the working 
standard of 100 µg/ml. Aliquots of 0.2ml to 0.7ml from the stock solution representing 
2to7µg/ml of drug were transferred to 10 ml volumetric flask and the volume was adjusted to 
10 ml with 0.1N HCl. Absorbance of the above solutions was taken at λmax 227nm against the 
blank solution prepared in the same manner without adding the drug. A graph of absorbance 
Vs concentration was plotted and was found to be linear over a range of 2 to 7µg/ml 
indicating its compliance with Beer’s law. 
 
Calibration curve of Model drug in Purified Water 
Procedure: 10 mg of model drug was  dissolved in 100 ml of distilled water to obtain the 
working standard of 100 µg/ml. Aliquots of 0.2 ml to 0.7 ml from the stock solution 
representing 2to7µg/ml of drug were transferred to 10 ml volumetric flask and the volume 
was adjusted to 10 ml with purified water. The Absorbance of the above solutions was taken 
at λmax 227 nm against the blank solution prepared in the same manner without adding the 
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drug. A graph of absorbance Vs concentration was plotted and was found to be linear over a 
range of 2 to7µg/ml indicating its compliance with Beer’s law. 
 
Calibration curve of Model drug in pH 6.8 Phosphate buffer 
Procedure: 10 mg of model drug was dissolved in 100 ml of the pH 6.8 buffer to obtain the 
working standard of 100 µg/ml. Aliquots of 0.2 to 0.7ml from the stock solution representing 
2to7µg/ml of drug were transferred to 10 ml volumetric flask and the volume was adjusted to 
10 ml with the pH 6.8 buffer.Absorbance of the above solutions was taken at λmax 227 nm 
against the blank solution prepared in the same manner without adding the drug. A graph of 
absorbance Vs concentration was plotted and was found to be linear over a range of 2 to 7 
µg/ml indicating its compliance with Beer’s law 
 
Calibration curve of Model drug in pH 4.5 acetate buffer 
Procedure: 10 mg of model drug was dissolved in 100 ml of the pH 4.5 buffer to obtain the 
working standard of 100 µg/ml. Aliquots of 0.2 to 0.7ml from the stock solution representing 
2to7µg/ml of drug were transferred to 10 ml volumetric flask and the volume was adjusted to 
10 ml with the pH 4.5 buffer.Absorbance of the above solutions was taken at λmax 227 nm 
against the blank solution prepared in the same manner without adding the drug. A graph of 
absorbance Vs concentration was plotted and was found to be linear over a range of 2 to 7 
µg/ml indicating its compliance with Beer’s la 
 
9.3. Drug and excipients interaction study 
Differential Scanning Calorimetry 
The possibility of any interaction between drug and excipients  used in the formulation of 
tablets was assessed by carrying out the thermal analysis of drug, excipients and physical 
mixture of drug and excipients(Initial and stability charged).The thermal behavior of plain 
drug, excipients and physical mixturewere determined using differential scanning calorimeter 
at heating rate of  20°C /min. The measurements were performed at a heating range of 25 to 
2500C under nitrogen atmosphere. 
 
9.4. X-Ray Diffraction study of model drug 
Crystallinity of the drug was determined using the Bruker D8 Advance XRD with copper 
target. The conditions were: 40 Kv voltages; 40 mA current; at room temperature. The drug 
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was loaded on to the diffractometer and scanned over a range of 2θ values from 30 to 450 at a 
scan rate of 0.1 0 /sec. 
 
9.5. Fourier Transform Infra Red spectrum of model drug 
FTIR was performed by KBr pellet method. Drug and KBr were taken in 1:100 ratio 
and ground in mortar for even distribution of sample and KBr. Then it was prepared in the 
form of disk by applying pressure of 5 tons for 5 min using a hydraulic press and subjected to 
IR. The software used was spectrum (version 6.1.0) in the wave number range of 400-4000 
cm -1. The resolution is 4 cm -1. 
 
9.6. Characterisation of API 
Particle size determination: Dry sieve analysis for particle size determination 
Dry Sieving Method 
An accurately weighed quantity of test specimen was placed on the top (coarsest) sieve, and lid 
was replaced. The nest of sieves was agitated for 5 minutes. Then each sieve was carefully 
removed from the nest without loss of material. Each sieve was reweighed, and the weight of 
material on each sieve was determined. The weight of material in the collecting pan was also 
determined in a similar manner. The nest of sieves were reassembled and agitated for 5 
minutes. Each sieve was removed and weighed, as previously described. Upon completion of 
the analysis, the weights of material were reconciled. Total losses must not exceed 5% of the 
weight of the original test specimen. 
 
Flow properties of API 
Bulk density: 
Bulk density was determined by measuring the volume of a known mass of powder 
sample that has been passed through a screen into a graduated cylinder (USP Method I). 
Approximately 10gm of test sample, M was introduced into 25 mL dry measuring cylinder 
without compacting. The powder was leveled carefully without compacting and read the 
unsettled apparent volume V0, to the nearest graduated unit. Bulk density was calculated, in g 
per ml, by the formula. 
(M) / (Vo) 
Generally replicate determinations are desirable for the determination of this property. 
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Tapped density: 
Tapped density was achieved by mechanically tapping a measuring cylinder containing a 
powder sample. After measuring the initial weight and volume, the cylinder was 
mechanically tapped, and volume readings were taken until little further volume change is 
observed.  
Procedure: 
Cylinder containing the sample was tapped mechanically by raising the cylinder and allowing 
it to drop under its own weight using a suitable mechanical tapped density tester that provides 
a fixed drop of 14 ± 2 mm at a nominal rate of 300 drops per minute. Unless otherwise 
specified, the cylinder was tapped 500 times initially and the tapped volume was measured, 
Va, to the nearest graduated unit. The tapping was repeatedfor an additional 750 times and the 
tapped volume was measured, Vb, to the nearest graduated unit.If the difference between the 
two volumes is less than 2%, Vb is the final tapped volume, Vf . It was repeated in increments 
of 1250 taps, as needed, until the difference between succeeding measurements is less than 
2%. The tapped density was calculated, in g per mL, by the formula:  
(M) / (Vf). 
Generally replicate determinations are desirable for the determination of this property. 
Compressibility Index:  
The Compressibility Index and Hausner Ratio are measures of the propensity of a 
powder to be compressed. As such, they are measures of the relative importance of 
interparticulate interactions. In a free-flowing powder, such interactions are generally less 
significant, and the bulk and tapped densities will be closer in value. For poorer flowing 
materials, there are frequently greater interparticle interactions, and a greater difference 
between the bulk and tapped densities will be observed. These differences are reflected in the 
Compressibility Index and the Hausner Ratio. 
Compressibility Index— Calculate by the formula:  
 
CI (%) =     Vo-Vf  x 100 
          Vo 
Hausner Ratio— Calculate by the formula:  
HR  =       Vf 
        Vo 
         Where V0  -   Bulk volume  
     Vf  -   Tapped volume 
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                                               Table.18. Scale of Flowability (USP) 
Compressibility Index (%) Flow Character Hausner’s Ratio 
≤ 10 Excellent 1.00-1.11 
11-15 Good 1.12-1.18 
16-20 Fair 1.19-1.25 
21-25 Passable 1.26-1.34 
26-31 Poor 1.35-1.45 
32-37 Very Poor 1.46-1.59 
> 38 Very, very Poor > 1.60 
 
 
Determination of Angle of Repose 
The angle of repose has been used to characterize the flow properties of solids. Angle 
of repose is a characteristic related to interparticulate friction or resistance to movement 
between particles. 
Angle of repose was formed on a fixed base with a retaining lip to retain a layer of 
powder on the base. The base should be free of vibration. The height of the funnel was varied 
to carefully build up a symmetrical cone of powder. Care should be taken to prevent vibration 
as the funnel is moved. The funnel height should be maintained approximately 2–4 cm from 
the top of the powder pile as it is being formed in order to minimize the impact of falling 
powder on the tip of the cone. If a symmetrical cone of powder cannot be successfully or 
reproducibly prepared, this method is not appropriate. Angle of repose was determined by 
measuring the height of the cone of powder and calculating the angle of repose, from the 
following equation: 
 tan α = h/r 
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Table.19. Flow Properties and Corresponding Angles of Repose 
Flow Property Angle of Repose (degrees) 
Excellent 25–30 
Good 31–35 
Fair—aid not needed 36–40 
Passable—may hang up 41–45 
Poor—must agitate, vibrate 46–55 
Very poor 56–65 
Very, very poor >66 
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X.METHODOLOGY 
 
Formulation Development of ODT 
 
10.1.Preparation of ODT using wet granulation  technique 
Orodispersible tablets were prepared by mixing API with intra granular excipients and then binder 
solution which was prepared by dissolving binder (klucelexf) in sufficient quantity of water was 
added. Then it was mixed well to form a damp mass. After that it was passed through 16 mesh to 
form granules.Then the granules were dried and the extra granular excipients were added and 
finally compressed to tablets. 
 
10.2.Optimisation of composition  
 Trial with different disintegrants 
Orodispersible tablets using wet granulation were prepared by taking  different disintegrants  
like sodiumstarchglycolate, croscarmellose sodium,polyplasdoneXL-10and kyron T-314 and 
then disintegrant was optimized based on disintegration time. 
 
 Trial with different concentrations of  excipients 
ODT’S were prepared by taking different concentrations of excipients and then optimized. 
 
10.3.Process optimization 
 Hardness challenge study 
 Orodispersible tablets were formulated  at different hardness levels and then optimized. 
 
10.4. FOMULATION DESIGN 
Table.20.Optimization with different disintegrants 
Ingredients F-1 F-2 F-3 F-4 
Intragranular Batch size 500   
API 8.75 8.75 8.75 8.75 
Avicel PH-101 20 20 20 20 
Aspartame 8 8 8 8 
Polyplasdone xl-10 10 - - - 
Sodium starch glycolate - 10 - - 
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Croscarmellose sodium - - 10 - 
Kyron T-314 - - - 10 
Mannitol25C 53.25 53.25 53.25 53.25 
Aerosil200 5 5 5 5 
Klucel-EXF 3 3 3 3 
Purified water 50 50 50 50 
Extragranular Batch size 300   
MannitolSD200 51 51 51 51 
PolyplasdoneXL-10 10 - - - 
Sodium starch glycolate - 10 - - 
Croscarmellose sodium - - 10 - 
Kyron T-314 - - - 10 
AvicelPH-102 15 15 15 15 
Aspartame 8 8 8 8 
Peppermint flavour 1 1 1 1 
Aerosil200 2 2 2 2 
Sodium stearylfumarate 5 5 5 5 
Totalweight (mg/tablet) 200 200 200 200 
F1-Polyplasdonexl-10 
F2-Sodiumstarchglycolate 
F3-Croscarmellosesodium 
F4-KyronT-314 
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Table.21.Optimisation with different concentrations of excipients 
Ingredients F-5 F-6 F-7  F-8  F-9 F-10  F-11  
Intragranular        
API 8.75 8.75 8.75 8.75 8.75 8.75 8.75 
Avicel PH-101 20 20 20 20 20 20 15 
Aspartame 5 - 8 8 8 8 8 
Polyplasdone xl-10 10 10 5 10 15 - 10 
Mannitol25C 56.25 61 58.25 53.25 48.25 63.25 58.25 
Aerosil200 5 5 5 5 5 5 5 
Klucel-EXF 3 3 3 3 3 3 3 
Purified water 50 50 50 50 50 50 50 
Extragranular        
MannitolSD200 54 59 56 51 46 61 56 
PolyplasdoneXL-10 10 10 5 10 15 - 10 
AvicelPH-102 15 15 15 15 15 15 10 
Aspartame 5 - 8 8 8 8 8 
Peppermint flavour 1 1 1 1 1 1 1 
Aerosil200 2 2 2 2 2 2 2 
Sodium stearylfumarate 5 5 5 5 5 5 5 
Totalweight (mg/tablet) 200 200 200 200 200 200 200 
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Ingredients F-12 F-13 F-14 F-15 F-16 
Intragranular      
API 8.75 8.75 8.75 8.75 8.75 
Avicel PH-101 25 - 20 20 20 
Aspartame 8 8 8 8 8 
Polyplasdone xl-10 10 10 10 - 10 
Mannitol25C 48.25 73.25 46.25 56.25 53.25 
Aerosil200 5 5 5 5 5 
Klucel-EXF 3 3 10 - 3 
Purified water 50 50 50 50 50 
Extragranular      
MannitolSD200 46 66 51 51 48 
PolyplasdoneXL-10 10 10 10 10 10 
AvicelPH-102 20 - 15 15 15 
Aspartame 8 8 8 8 8 
Peppermint flavour 1 1 1 1 1 
Aerosil200 2 2 2 2 2 
Sodium stearylfumarate 5 5 5 5 8 
Totalweight (mg/tablet) 200 200 200 200 200 
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Ingredients F-17  F-18  F-19  F-20  
Intragranular     
API 8.75 8.75 8.75 8.75 
Avicel PH-101 20 20 20 20 
Aspartame 8 8 8 8 
Polyplasdone xl-10 10 10 10 - 
Mannitol25C 53.25 53.25 53.25 58.25 
Aerosil200 5 5 5 - 
Klucel-EXF 3 3 3 - 
Purified water 50 50 50 50 
Extragranular     
MannitolSD200 56 50 53 51 
PolyplasdoneXL-10 10 10 10 10 
AvicelPH-102 20 - 15 15 
Aspartame 8 8 8 8 
Peppermint flavour 1 1 1 1 
Aerosil200 2 3 - 2 
Sodium stearylfumarate - 5 5 5 
Totalweight(mg/tablet) 200 200 200 200 
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XI. EVALUATION PARAMETERS OF ODT 
11.1. Precompression parameters 
 Blend Characterization 
Blend Characterizationparameters such as bulk density, tapped density, Compressibility 
Index, Hausner’s ratio, Angle of Repose were performed and computed to 12 formulations of 
trial batches.  
 
11.2.Postcompression parameters 
All the batches of tablets were evaluated for various physical parameters like thickness, 
weight variation, friability, hardness, drug content and dissolution as per pharmacopoeial 
standards.12 
 
A. Weight variation: 
20 tablets were taken and weighed individuallyon a digital weighing balance. Average 
weight was calculated and the individual tablet weight was compared to the average. The 
tablet pass the U.S.P. test if no more that 2 tablets are outside the percentage limit and if no 
tablet differs by more than 2 times the percentage limit.  
 
Average weight =    Weight of 20 tablets 
       20 
Table.22.Acceptance criteria for tablet weight variation 
Average weight of tablet(mg) % difference allowed 
130 or Less than ± 10 
130-324 ± 7.5 
More than 324 ± 5 
 
B.Thickness: 
Thickness of tablet is important for uniformity of tablet size. Thickness of tablets can vary 
with no change in weight because of the difference in the density of the granulation and the 
pressure applied to the tablets, as well as the speed of the compression machine. Ten tablets 
were randomly selected and thickness was measured using vernier calipers and recorded 
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C.Crushing strength: 
Tablet requires a certain amount of strength or hardness and resistance to friability to 
withstand mechanical shakes of handling in manufacture, packaging and shipping. Hardness 
generally measures the tablet crushing strength. Changes in hardness results in differences in 
disintegration and dissolution characteristics. The crushing strength of the tablet was 
determined using Schleuniger hardness tester. 
 D.Friability test: 
This test is performed to evaluate the ability of tablets to withstand abrasion in packing, 
handling and transporting. For tablets weighing up to 650 mg each, take a sample consisting 
of the minimum number of tablets that makes a total mass of more than 6.5 gm. For tablets 
weighing more than 650 mg each take a sample of ten tablets. Dust should be carefully 
removed from the tablets prior to testing. Accurately weigh the tablet sample, and place the 
tablets in the drum. Rotate the drum 100 times, at 24-26 revolutions per minute and remove 
the tablets. Remove any loose dust from the tablets as before. If no tablets are cracked, split 
or broken, accurately weigh the tablets, and determine the friability (mass per cent of the lost 
mass with respect to the initial mass). 
 
%Friability = (Loss in weight / Initial weight) x 100 
 
E) Content uniformity test: 
Ten tablets from each formulation were powdered. The powdered sample equivalent 
to 200 mg of drug was transferred to a volumetric flask and dissolved in required amount of 
0.1NHCl suitably diluted with media and drug content was analyzedagainst blank by UV 
spectrophotometer at 227 nm. The percentage of drug present in the tablets was calculated. 
 
F.Disintegration test 
The time for disintegration of ODTs isgenerally less than one minute and actualdisintegration 
time that patient can experienceranges from 5-30 seconds. The standard procedure of 
performing disintegration test forthese dosage forms has several limitationsand they are not 
suitable for the measurementof very short disintegration times. The methodneeds to be 
modified for ODTs asdisintegration is required without water; thusthe test should mimic 
disintegration in salivarycontents. A modified dissolution apparatus isapplied to an ODT with 
a disintegration timethat is too fast to distinguish differences between tablets when the 
compendial methodis used. A basket sinker containing the tabletsis placed just below the 
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water surface in acontainer with 900 mL of water at 37 0C, and a paddle rotating at 100 rpm 
is used. Thedisintegration time is determined when thetablet has completely disintegrated and 
passed through the screen of the sinker 
G.Wetting time 
A study on wetting time reported the use of a piece of double folded tissue paper placed in a 
petridish containing 6ml of water.One tablet was placed on this paper and the time for 
complete wetting of the tablet was noted. 
H.Moisture uptake study17-18 
ODTs usually contain high concentration of hydrophilic excipients with the minimum 
possible hardness which together contributes to their increased susceptibility to moisture 
uptake. In order to maintain their physical integrity and surface texture, special attention is 
required during storage and packaging of these dosage forms. Therefore moisture uptake 
studies are recommended for ODTs. 
The test can be carried out by keeping ten tablets along with calcium chloride in a dessicator 
maintained at 37C for 24hrs to ensure complete drying of the tablets. The tablets are then 
weighed and exposed to 75%RH, at room temperature for 2 weeks. The required humidity 
can be achieved by keeping saturated sodium chloride solution in the dessicator for 24hrs.The 
tablets were reweighed and the percentage increase in weight is recorded. If the moisture 
uptake is high it requires special dehumidified area for manufacturing and packing. The 
materials with high moisture resistant properties should be used for packaging e.g. alu strip 
pack, alu-alu blister or polyethylene sealing on blister. 
 
I. Fitness of dispersion  
This is a qualitative test specified by EP for dispersible tablets. It is an assessment of the 
grittiness which arises due to disintegration of the tablet into coarse particles. The test is 
performed by placing two tablets in 100ml of water and stirring it gently,till the tablets get 
completely disintegrated.The formulation is considered to form a smooth dispersion if the 
complete dispersion passes through a sieve screen with a nominal mesh aperture of 710µm 
without leaving any residue on the mesh. 
Optimized formulation forms a smooth dispersion without leaving any residue on the mesh. 
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11.3 Taste evaluation 
Taste evaluation wasdone in six healthy human volunteers by holding tablet in the  mouth for 
5 to 10 sec, then were asked to spit out;  followed by rinsing the mouth by distilled water and 
the bitterness level was then recorded 
 
XII.Accelerated Stability study of the optimized batch  
In order to determine the change in evaluation parameters and in vitro release profile on 
storage, stability study of optimized batch  was carried out at accelerated storage condition at 
temperature 40° ± 2° C and 75% ± 5% RH in a humidity chamber for 1 month. Sample were 
withdrawn after 30 days interval and evaluated for change in  physical appearance 
 
. XIII.In vitro dissolution studies: 12 
Dissolution study was conducted for formulations with different disintegrants using 
USP type-II apparatus (ELECTROLAB). The dissolution test was performed in buffers of 
different pH(0.1N HCl,6.8Phosphate buffer,4.5Acetate buffer, Water)50rpm and at a 
temperature of 370C±0.50C for 30 minutes. Ten milliliters of aliquots were periodically 
withdrawn at time intervals of 5, 10, 15, 20,and 30minutes. Then the sample volume was 
replaced with an equal volume of fresh dissolution medium. The samples were diluted and 
analyzed spectrophotometrically at 227nm. 
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